Coherus BioSciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.03-14

Coherus BioSciences (NASDAQ:CHRS) Full Year 2024 Results

Key Financial Results

Revenue: US$267.0m (up 3.8% from FY 2023).
Net income: US$28.5m (up from US$237.9m loss in FY 2023).
Profit margin: 11% (up from net loss in FY 2023).
EPS: US$0.25 (up from US$2.53 loss in FY 2023).

CHRS Post-Clinical Trial Products

Launched (during full year): 1.

NasdaqGM:CHRS Revenue and Expenses Breakdown March 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Coherus BioSciences Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.5%. Earnings per share (EPS) also surpassed analyst estimates by 31%.

In the last 12 months, the only revenue segment was Developing and Commercializing Biosimilar Products contributing US$267.0m. The largest operating expense was General & Administrative costs, amounting to US$161.1m (63% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$133.5m. Explore how CHRS's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 10% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 5 warning signs for Coherus BioSciences (4 shouldn't be ignored!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.